Chemotherapies and targeted agents continue to dominate the treatment of colorectal cancer, although targeted agents (e.g., Avastin, Erbitux, Vectibix) are currently confined to the metastatic setting. The FDA approvals of the PD-1 inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol-Myers Squibb) in 2017 and of Opdivo plus Yervoy in 2018 for microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR) metastatic colorectal cancer herald the entry of immunotherapy treatments to this biomarker-defined patient population.
- What is the uptake of Keytruda and Opdivo in the previously treated MSI-H/dMMR metastatic colorectal cancer segment in the United States, and what are the main obstacles to prescribing these immunotherapies?
- What is the patient share of key therapies used to treat RASwild-type and RAS-mutant metastatic colorectal cancer?
- What drivers and obstacles influence treatment decisions in the metastatic setting for select targeted therapies?
- How do drug-treatment rates vary between key colorectal cancer patient segments, according to biomarker status and line of therapy?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Geographies: United States
Primary Research: Survey of 100 medical oncologists in the United States
Key Drugs Covered: Avastin, Erbitux, Vectibix, Lonsurf, Keytruda, Opdivo, Zaltrap, Cyramza, Stivarga, Yervoy
- Detailed, Expanded Analysis (US)
- Current Treatment Physician Insights Colorectal Cancer US [October] 2019
Author(s): Priti Girotra, M.Pharm., Ph.D
Priti Girotra, , is an analyst in the oncology team at Decision Resources Group and has authored insightful content on multiple indications including Non-Small-Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Cancer, Malignant Melanoma, and Multiple Myeloma. Prior to joining DRG, Dr. Girotra conducted her research on formulation optimization of nanoparticles containing triptan derivatives for effective brain targeting and therapeutic management of migraine, under a DST-INSPIRE Fellowship at University of Science & Technology, Hisar, India.